Business Context and Reporting Period
This Form 8-K was filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on February 28, 2018. The report details a corporate event occurring on the same date regarding the partial exercise of an underwriters' over-allotment option.
Key Financial Metrics
- Shares Issued: 414,996 shares of common stock.
- Offering Price: $5.50 per share.
- Net Proceeds: Approximately $2.1 million (after deducting underwriting commissions, discounts, and offering expenses).
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, net income, operating cash flow, or margins.
- Debt/Liquidity: The filing text does not provide a clear value for total debt or liquidity ratios.
Material Changes
The primary material change is the increase in outstanding common stock and cash assets resulting from the Option Exercise. This transaction was executed pursuant to an underwriting agreement dated February 8, 2018, involving Jefferies LLC, Evercore Group L.L.C., and Deutsche Bank Securities Inc.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard legal disclaimer that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the correct registrant name is Miragen Therapeutics, Inc., not Viridian Therapeutics, Inc.
- Confirm the total number of shares outstanding post-transaction by reviewing the company's latest 10-K or 10-Q.
- Review the full underwriting agreement dated February 8, 2018, for details on the initial offering and remaining over-allotment options.
- Assess the impact of the $2.1 million net proceeds on the company's cash runway given its pre-revenue or early-stage status.